- United States
- /
- Professional Services
- /
- NasdaqGS:EXPO
Exponent, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
As you might know, Exponent, Inc. (NASDAQ:EXPO) recently reported its second-quarter numbers. Revenues were US$132m, approximately in line with expectations, although statutory earnings per share (EPS) performed substantially better. EPS of US$0.57 were also better than expected, beating analyst predictions by 13%. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Exponent after the latest results.
Check out our latest analysis for Exponent
Following last week's earnings report, Exponent's three analysts are forecasting 2024 revenues to be US$516.3m, approximately in line with the last 12 months. Statutory per-share earnings are expected to be US$2.05, roughly flat on the last 12 months. Before this earnings report, the analysts had been forecasting revenues of US$509.4m and earnings per share (EPS) of US$1.93 in 2024. So the consensus seems to have become somewhat more optimistic on Exponent's earnings potential following these results.
The analysts have been lifting their price targets on the back of the earnings upgrade, with the consensus price target rising 22% to US$115. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. There are some variant perceptions on Exponent, with the most bullish analyst valuing it at US$120 and the most bearish at US$110 per share. With such a narrow range of valuations, the analysts apparently share similar views on what they think the business is worth.
Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. We would highlight that Exponent's revenue growth is expected to slow, with the forecast 3.1% annualised growth rate until the end of 2024 being well below the historical 7.0% p.a. growth over the last five years. Compare this against other companies (with analyst forecasts) in the industry, which are in aggregate expected to see revenue growth of 6.2% annually. So it's pretty clear that, while revenue growth is expected to slow down, the wider industry is also expected to grow faster than Exponent.
The Bottom Line
The biggest takeaway for us is the consensus earnings per share upgrade, which suggests a clear improvement in sentiment around Exponent's earnings potential next year. On the plus side, there were no major changes to revenue estimates; although forecasts imply they will perform worse than the wider industry. We note an upgrade to the price target, suggesting that the analysts believes the intrinsic value of the business is likely to improve over time.
With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have forecasts for Exponent going out to 2026, and you can see them free on our platform here.
We don't want to rain on the parade too much, but we did also find 1 warning sign for Exponent that you need to be mindful of.
Valuation is complex, but we're here to simplify it.
Discover if Exponent might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About NasdaqGS:EXPO
Exponent
Operates as a science and engineering consulting company in the United States and internationally.
Flawless balance sheet with proven track record and pays a dividend.